

Miguel-Angel Perales, M.D.
Deputy Chief, Adult Bone Marrow Transplantation Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
1275 York Avenue, Box 298
New York, NY 10065
Work (212) 639-8682
E-Mail: peralesm@mskcc.org

Education

1991 MD, Free University of Brussels, Brussels, Belgium, Magna cum Laude.

Postdoctoral Training

1991 – 1995 Postdoctoral Fellow, Department of Medicine, Division of Hematology-Oncology, Tufts - New England Medical Center, Boston, Massachusetts.
1995 – 1996 Intern, Internal Medicine, Tufts - New England Medical Center, Boston, Massachusetts.
1996 – 1998 Resident, Internal Medicine, Tufts - New England Medical Center, Boston, Massachusetts.
1998 – 2001 Fellow, Medical Oncology-Hematology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
1998 – 2001 Fellow in Medicine, Weill Cornell Medical College, New York, NY.

Academic Appointments

2001 – 2004 Instructor, Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
2001 – 2008 Instructor in Medicine, Weill Cornell Medical College, New York, NY.
2004 – 2013 Assistant Member, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
2004 – 2013 Assistant Attending Physician, Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, New York, NY.
2008 – 2013 Assistant Professor, Department of Medicine, Weill Cornell Medical College, New York, NY.
2007 – present Director, Adult BMT Fellowship Program, Memorial Sloan Kettering Cancer Center, New York, NY.
2012 – present Deputy Chief, Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, New York, NY.
2013 – present Associate Member, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
2013 – present Associate Attending Physician, Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, New York, NY.
2013 – present Associate Professor, Department of Medicine, Weill Cornell Medical College, New York, NY.

2013 – present Special Contributing Faculty Member, Gerstner Sloan Kettering Graduate School, MSKCC, New York, NY.

Certificates/ Licensures

1998 New York State Medical License.
1998 American Board of Internal Medicine: Internal Medicine.
2002 American Board of Internal Medicine: Medical Oncology.

Hospital Committees

2009 – present Member, Data Safety Monitoring Committee, Memorial Sloan Kettering Cancer Center, New York, NY.
2009 – 2013 Member, Clinical Council, Memorial Sloan Kettering Cancer Center, New York, NY.
2012 – present Member, Medicine Protocol Review Committee, Memorial Sloan Kettering Cancer Center, New York, NY.
2013 Member, Search Committee, Director of Hospital Infection Control, Memorial Sloan Kettering Cancer Center, New York, NY.
2015 – present Member, Search Committee, Pulmonary Service Chief, Memorial Sloan Kettering Cancer Center, New York, NY.

Extramural Committees

2005 – present Member, ALLIANCE (CALGB), Transplant Committee
2011 – present Member, American Society for Blood and Marrow Transplantation (ASBMT), Educational Committee
2012 – present Co-Chair, Center for International Blood and Marrow Transplant Research (CIBMTR), Graft Sources and Manipulation Working Committee
2012 – present Member, National Marrow Donor Program (NMDP), System Capacity Initiative Physician Working Group and Curriculum Sub-Group
2013 – present Member, ASBMT, Committee on Practice Guidelines
2013 Member, ASBMT-GETH Fellowship Selection Committee
2013 – present Member, ASBMT, Educational Committee, Sub-Committee on Web-Based Learning
2013 – present Co-Chair, BMT-CTN Social Media Task Force
2013 – present Member, Data Safety Monitoring Board, Tufts Medical Center, Boston, MA.
2014 – present Member, Scientific and Medical Advisory Board, ImmunID, Grenoble, France
2014 – 2015 Chair, Digital Education Working Group, American Society of Hematology (ASH) Committee on Educational Affairs
2014 – present Co-Chair, BMT-CTN Chemotherapy Dosing Task Force
2015 – present Co-Chair, ASBMT Educational Committee
2015 – 2016 Chair, ASBMT Educational Committee Sub-Committee on Web-Based Learning
2015 – present Member, ASBMT Task Force on Business Development
2015 – present Member, CIBMTR Cellular Therapies Task Force
2015 – present Member, ASBMT-FACT-NMDP Education Consortium
2015 – present Member, Board of Directors, Be The Match – National Marrow Donor Program
2016 – present Member, ASH Committee on Educational Affairs, Teaching Cases Subcommittee

- 2016 – present Member at Large (North America) CIBMTR Advisory Committee.
- 2016 – present Member, American Association for Cancer Research (AACR) Cancer Immunology Working Group (CIMM) Steering Committee
- 2016 – present Member, Data Safety Monitoring Board, Servier, Suresnes, France
- 2017 – present Member, ASH Committee on Educational Affairs
- 2017 – present Member, BMT-CTN Biomarkers Committee

Study Sections

- 2003 – 2009 Congressionally Directed Medical Research Program (CDMRP, DOD) Prostate Cancer Immunological Sciences – Grant Review Panel
- 2006 NIH-RAID Pilot (Rapid Access to Interventional Development) – Grant Review Panel (ad hoc member)
- 2008 NIH-CONC (Clinical Oncology Study Section – ad hoc member)
- 2010 Congressionally Directed Medical Research Program (CDMRP, DOD) Skin Cancer Concept – Grant Review Panel
- 2013 Cycle for Survival (MSKCC)
- 2013 New York State Empire Clinical Research Investigator Program
- 2013 Programme de Recherche Translationnelle en Santé, Agence Nationale de la Recherche, France
- 2013 ASBMT New Investigator Award
- 2015 Cycle for Survival (MSKCC)
- 2016 KWF (Dutch Cancer Society)

Honors and Awards

- 1985 De Craene Scholarship, Free University of Brussels, Belgium.
- 1990 ERASMUS grant, European Community Commission.
- 2000 Charles A. Dana Fellow, MSKCC
- 2000 International Society for Interferon and Cytokine Research Travel Award
- 2000 American Society of Hematology Travel Award
- 2005 American Society for Clinical Investigation Travel Award
- 2015 Blood and Marrow Transplantation Clinical Trials Network (BMT CTN) Purple Heart Award for Exemplary Service

Scientific and Medical Societies

American Association for Cancer Research
 American College of Physicians
 American Society for Clinical Oncology
 American Society of Hematology
 American Society for Blood and Marrow Transplantation
 International Society for Interferon and Cytokine Research
 Massachusetts Medical Society

Mentoring

Fariborz (Fred) Mortazavi MD (Research fellow, MSKCC)	2002 – 2003
Rob Jenq MD (Hematology-Oncology fellow, MSKCC)	2005 – 2007
C. Joy Somberg MD (Research fellow, MSKCC)	2006 – 2007
Jenna Goldberg MD (Hematology-Oncology fellow, MSKCC)	2008 – 2010
Kuan-Chi Lai (Master thesis advisor (Epidemiology), Columbia University)	2008 – 2009
Alex Linker (Medical student, Columbia University)	2009 – 2010
Ravin Ratan MD (Medical resident, WCMC/NYH)	2010 – 2012
Jenna Goldberg MD (Junior faculty, MSKCC)	2010 – 2014
Izaskun Ceberio MD (Faculty, University of Navarra, Spain)	2011 – 2013
Gabriela Soriano Hobbs MD (Hematology-Oncology fellow, MSKCC)	2012 – 2014
Alberto Mussetti MD (Research fellow, Istituto Nazionale dei Tumori, Milan)	2013 – 2014
Pere Barba MD (Research fellow, Vall d'Hebron Institute of Oncology, Barcelona, Spain)	2015
Christina Cho MD (Hematology-Oncology fellow, MSKCC)	2015 – present
Claudia Rosilo Gil (Medical student, Universitat de Barcelona, Spain)	2015
Ana Maria Avila (Medical student, La Sabana University, Bogota, Colombia)	2015

Funding

2000 – 2002	Funder: NIH/NCI (T32 award, Clinical Scholars Biomedical Research Training Program, MSKCC). Title: <i>Development of Rational Vaccine Strategies for Cancer</i>
2002 – 2003	Funder: Bioject, Inc. Title: <i>Mechanisms of DNA immunization using the Biojector</i> . Role: PI.
2003	Funder: MSKCC Translational and Integrative Medicine Research Fund. Title: <i>Molecular Adjuvants For Cancer Vaccines</i> Role: PI.
2003	Funder: Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research, and The Experimental Therapeutics Center of MSKCC. Title: <i>GM-CSF DNA: A Molecular Adjuvant for Cancer Vaccines</i> Role: PI
2003 – 2007	Funder: NIH (K08 award). Title: <i>Optimizing T cell Immunity to Cancer Vaccines</i> Role: PI
2004 – 2005	Funder: MSKCC Byrne Fund. Title: <i>Strategies to Enhance Post-Transplant Tumor Vaccination</i> Role: PI
2005 – 2007	Funder: Leukemia and Lymphoma Society. Title: <i>Interleukin-7 as a novel therapy to overcome post-transplant immunoincompetence in recipients of allogeneic stem cell grafts</i> . Role: co-PI (PI van den Brink)
2005 – 2010	Funder: NIH/NCI (P01 Award, Biological approaches to the treatment of cancer, PI Houghton). Project 4 (van den Brink): <i>DNA vaccination and adoptive cell therapy following hematopoietic stem cell transplantation</i> Role: co-investigator
2007 - 2008	Funder: MSKCC Translational and Integrative Medicine Research Fund. Title: <i>Interleukin-7: a novel therapy to overcome post-transplant immunodeficiency in recipients of allogeneic hematopoietic stem cell transplants</i> Role: PI.

- 2009 – 2010 Funder: New York State Empire Clinical Research Investigator Program (support for BMT fellow). Title: *Immune recovery after allogeneic hematopoietic stem cell transplant*
Role: PI
- 2009 – 2012 Funder: Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research, and The Experimental Therapeutics Center of MSKCC (competitive renewal – 2011). Title: *T-cell precursors in allogeneic hematopoietic stem cell transplant*
Role: PI
- 2010 – 2011 Funder: New York State Empire Clinical Research Investigator Program (support for BMT fellow). Title: *Transplant Access in Racial and Ethnic Minorities*
Role: Program Director (PI Barker)
- 2009 – 2010 Funder: NIH (ARRA Supplement Funding for Pilot Projects). Title: *Administration of T cell precursors in recipients of an allogeneic hematopoietic stem cell transplant: a novel approach to enhance T cell recovery, function and anti-tumor activity in patients with advanced lymphoid malignancies*
Role: PI
- 2010 – 2012 Funder: New York Community Trust. Title: *T cell precursors in Allogeneic Hematopoietic Stem Cell Transplantation*
Role: PI
- 2010 – 2013 Funder: MSKCC Cycle for Survival. Title: *Targeting Acute Lymphoblastic Leukemia with T-cell Precursors in Allogeneic Hematopoietic Stem Cell Transplant*
Role: PI
- 2011 – 2012 Funder: When Everyone Survives. Title: *T cell precursors in Allogeneic Hematopoietic Stem Cell Transplantation*
Role: PI
- 2013 – 2018 NIH/NCI (P01 award, PI RJ O'Reilly), Core A: *Special Assessment of Graft Function Post Transplant*
Role: Core Director

Journals

2005 – 2007 Associate Editor, *Cytotherapy*
Ad-hoc Reviewer for the following Journals: *Blood, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, Cancer Immunology Immunotherapy, Clinical Infectious Diseases, Cytokines Cellular and Molecular Therapy, Cytotherapy, Leukemia, Vaccine.*

Meetings

- June 2004 Scientific Session discussant, ASCO Annual meeting, New Orleans, LA.
- Sept. 2006 Session Chair, Modern Vaccines/ Adjuvants and Delivery Systems, London, United Kingdom.
- Oct. 2007 Member, Organizing Committee for Cancer Vaccines/ Adjuvants/ Delivery for the next Decade, Heidelberg, Germany.
- Dec. 2007 Abstract reviewer and oral presentation chair-person, ASH Annual meeting, Atlanta, GA.
- Nov. 2009 Member, Organizing Committee for Cancer Vaccines/ Adjuvants/ Delivery for the next Decade, Dublin, Eire.
- Nov. 2012 Member, Prevention Protocol Development Team, 2nd International Workshop on the

Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, Bethesda, MD.

- Feb. 2014 Member, Organizing Committee, BMT Tandem Meetings, Dallas, TX
- Feb. 2014 Session chair-person, *Assessing Emerging Concepts in Immune Reconstitution*, BMT Tandem Meetings, Dallas, TX
- Dec. 2014 Abstract reviewer and oral presentation chair-person, ASH Annual meeting, San Francisco, CA
- Feb. 2015 Abstract reviewer and oral presentation chair-person, BMT Tandem Meetings, San Diego, CA
- Dec. 2015 Abstract Coordinating Reviewer, oral presentation chair-person, ASH Annual meeting, Orlando, FL
- Feb. 2016 Member, Organizing Committee, and Abstract Coordinating Reviewer, BMT Tandem Meetings, Honolulu, HI
- Feb. 2016 Session chair-person, *Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies*, BMT Tandem Meetings, Honolulu, HI
- Feb. 2017 Abstract reviewer, Late-breaking abstracts, BMT Tandem Meetings, Orlando, FL

Courses

- 2000 Attendee, AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, CO
- 2013 Attendee, Value Measurement for Health Care, Harvard Business School, Cambridge, MA
- 2014 Attendee, Association of American Medical Colleges Executive Development Seminar for Interim and Aspiring Leaders, Washington, DC

Clinical Trials

- 2000 MSKCC IRB 00-142: Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients with A Multi-Epitope Peptide Vaccine Using GM-CSF DNA as an Adjuvant: A Pilot Trial To Assess Safety and Immunity (NCI #5906). (*Role PI*)
- 2001 MSKCC IRB 01-149: A Ph 3 randomized, placebo-controlled, multi-ctr study of safety, efficacy, & pharmacokinetics of oral beclomethasone 17, 21-dipropionate in conjunction w/10 days of high-dose prednisone in pts w/grade II graft vs host disease with GI symptoms (*Role: Site PI*)
- 2005 MSKCC IRB 05-060: Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination with Corticosteroids (BMT-CTN 0302). (*Role: Site PI*)
- 2005 MSKCC IRB 05-061: A Phase I Study of CYT99 007 (Recombinant Human IL-7) In Adult Recipients of HLA Matched Ex Vivo T Cell Depleted Bone Marrow or Peripheral Blood Stem Cell Transplant. (*Role co-PI, PI van den Brink*)
- 2007 MSKCC IRB 07-147: An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma. (*Role PI*)
- 2007 MSKCC IRB 07-035: Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant. (*Role co-PI, PI Hsu*)
- 2007 MSKCC IRB 07-127: A Phase I Study of CYT 107 (Recombinant Glycosylated Human IL-7) in Recipients of HLA Matched Ex Vivo T Cell Depleted Peripheral Blood Stem Cells or Bone Marrow Transplants. (*Role co-PI, PI van den Brink*)

- 2009 MSKCC IRB 09-084: A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies (BMT CTN Protocol 0603). (*Role: Site PI*)
- 2009 MSKCC IRB 09-152: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Orbec (Oral Beclomethasone 17, 21-Dipropionate) in Conjunction with Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients with Gastrointestinal Graft vs. Host Disease BDP-GVHD-03. (*Role: Site PI*)
- 2011 MSKCC IRB 11-024: Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) (CALGB 100701; BMT CTN 0804). (*Role: Site PI*)
- 2012 MSKCC IRB 12-065: A Phase I Study of CD19-specific Genetically Modified T Cell Precursors in Patients with Advanced CD19-positive Hematologic Malignancies Undergoing T-cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation From HLA-matched, Related and Unrelated donors (IND Pending). (*Role PI*)
- 2012 MSKCC IRB 12-077: Phase II Study of Palifermin With Leuprolide Acetate For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation. (*Role PI*)
- 2013 MSKCC IRB 13-081: Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic Hematopoietic Cell Transplant (BMT CTN #1202). (*Role: Site PI, member BMT CTN study team*)
- 2013 MSKCC IRB 13-181: A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT. (*Role: Site PI*)
- 2013 MSKCC IRB 13-232: Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD). (*Role: Site PI*)
- 2014 MSKCC IRB 14-263: A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301). (*Role: BMT CTN Study co-chair*)
- 2015 MSKCC IRB 15-022: Pilot Trial of Homebound Stem Cell Transplantation. (*Role co-PI, PI Landau*)

Peer-Reviewed Articles

1. **Perales MA**, Sener A, Malaisse WJ. Hexose metabolism in pancreatic islets. The glucose-6-phosphatase riddle. *Mol Cell Biochem* 1991; 101:67-71.
2. **Perales MA**, Sener A, Malaisse WJ. Radioisotopic assay of aspartate and alanine aminotransferase in human plasma. *Clin Biochem* 1992; 25:105-107.
3. **Perales MA**, Schwartz DH, Fabry JA, Lieberman J. A vaccinia-gp160 based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1995; 10:27-35.
4. **Perales MA**, Skolnik PR, Lieberman J. The effect of Interleukin-12 on in vitro HIV-1 replication depends on clinical stage. *AIDS Res Hum Retroviruses* 1996; 12:659-668.
5. Trimble L, **Perales MA**, Knazek R, Lieberman J. Serum enhances the ex vivo generation of HIV-specific cytotoxic T cells. *Biotechnology and Bioengineering Journal* 1996; 50:521.
6. Wolchok JD, Srinivasan R, **Perales MA**, Houghton AN, Bowne WB, Blachere NE. Alternative roles for interferon- γ in the immune response to DNA vaccines encoding related melanosomal antigens. *Cancer Immunity*, 2001; 1:9.

7. Alpdogan O, Schmaltz C, Muriglan S, Kappel BJ, **Perales MA**, Rotolo JA, Halm JA, Rich BE, van den Brink MR. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. *Blood*, 2001; 98:2256-65.
8. Trcka J, Moroi Y, Clynes R, Goldberg SM, Bergtold A, **Perales MA**, Ma M, Ferrone CR, Carroll MC, Ravetch JV, Houghton AN. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. *Immunity*, 2002; 16:861-868.
9. **Perales MA**, Fantuzzi G, Goldberg, Turk MJ, Mortazavi F, Busam K, Houghton AN, Dinarello CA, Wolchok JD. GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. *Cytokines, Cellular and Molecular Therapy*, 2002; 7:125-133.
10. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, **Perales MA**, Mortazavi F, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens. *Vaccine*, 2004; 22:1700-1708.
11. Goldberg SM, Bartido SM, Gardner JP, Guevara-Patiño JA, Montgomery SC, **Perales MA**, Maughan MF, Dempsey J, Donovan GP, Olson WC, Houghton AN, Wolchok JD. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. *Clinical Cancer Research*, 2005; 11:8114-8121.
12. Cohen AD, Diab A, **Perales MA**, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN. Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity. *Cancer Res* 2006; 66:4904-4912.
13. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, **Perales MA**, Wolchok JD. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. *Vaccine* 2006; 24:4582-4585.
14. Jaffe D, Papadopoulos EB, Young JW, O'Reilly RJ, Prockop S, Kernan NA, Jakuboski A, Boulad F, **Perales MA**, Castro-Malaspina H, Small TN. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell transplantation (HCT). *Blood* 2006; 108:2470-2475.
15. **Perales MA**, Diab A, Cohen A, Huggins D, Guevara-Patiño JA, Hubbard VM, Engelhorn M, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, van den Brink M. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. *J Immunology* 2006; 177:4159-4167.
16. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Smith MO, Grubin J, Patel N, Chow A, Cabrera-Perez J, Radhakrishnan R, Diab A, **Perales MA**, Rizzuto G, Pamer EG, Heller G, Zúñiga-Pflücker JC, Alpdogan O, van den Brink MRM. Adoptive transfer of in vitro generated T cell precursors enhances donor T cell reconstitution and graft-versus-tumor activity in allogeneic hematopoietic stem cell transplantation recipients. *Nature Medicine* 2006; 12:1039-1047.
17. Ferrone CR, **Perales MA**, Goldberg SM, Somberg CJ, Hirschorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. *Clinical Cancer Research* 2006; 12:5511-5519.
18. Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, **Perales MA**, O'reilly RJ, Papadopoulos EB. Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified

- HLA-Matched Related or Unrelated Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Hematologic Malignancies. *Biol Blood Marrow Transplant*. 2007; 13:235-44.
19. Moskowitz A, Nolan C, Lis E, Castro-Malaspina H, **Perales MA**. Posterior reversible encephalopathy syndrome due to sirolimus. *Bone Marrow Transplantation* 2007; 39:653-4.
 20. **Perales MA**, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastgir H, Boulad F, Castro-Malaspina H, Heller G, Jakubowski AA, O'Reilly RJ, Small TN, Young JW, Kernan NA. Long-term follow-up of patients treated with daclizumab for steroid-refractory graft-vs-host disease. *Bone Marrow Transplantation* 2007; 40:481-486.
 21. Wolchok J, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, Ranganathan R, Zhang Y, Chapman PB, Krown SE, Livingston PO, Heywood M, Panageas KH, Terzulli SL, **Perales MA**. Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma. *Molecular Therapy* 2007; 15:2044-2050.
 22. Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, Heller G, Hsu KC, **Perales MA**, van den Brink MRM, Young JW, Prockop SE, Collins NH, O'Reilly RJ, Boulad F. Fludarabine-Based Conditioning Secures Engraftment of Second Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Initial Graft Failure. *Biol Blood Marrow Transplant*. 2007; 13:1313-1323.
 23. Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC, **Perales MA**, Collins N, Cisek C, Chiu M, van den Brink MR, O'reilly RJ, Papadopoulos EB. T-cell depleted stem cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of anti-thymocyte globulin. *Blood* 2007; 110:4552-4559.
 24. Castro-Malaspina H, Jakubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, **Perales MA**, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ. Induction of remission prior to transplantation improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell depleted stem cell transplants from HLA-identical siblings. *Biol Blood Marrow Transplant*. 2008; 14:458-468.
 25. Ostronoff F, **Perales MA**, Stubblefield MD, Hsu KC. Rituximab-responsive Guillain-Barre Syndrome following allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2008; 42:71-72.
 26. Pao M, Papadopoulos EB, Chou J, Heller G, Castro-Malaspina H, Jakubowski AA, Kernan NA, **Perales MA**, Prockop S, Scaradavou A, Young JW, van den Brink M, O'Reilly RJ, Small TN. Pneumococcal (PNCRM7) and Haemophilus influenza conjugate vaccine (HIB) responses in pediatric and adult recipients of allogeneic hematopoietic cell transplantation (alloHCT). *Biol Blood Marrow Transplant*. 2008;14:1022-1030.
 27. **Perales MA**, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB, Krown SE, Livingston PO, Ejadi S, Panageas KS, Engelhorn ME, Terzulli SL, Houghton AN, Wolchok JD. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. *Molecular Therapy* 2008; 16:2022-2029.
 28. Jenq RR, King CG, Volk C, Suh D, Smith OM, Rao U, Yim N, Holland A, Lu S, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan O, Penack O, Na IK, Kappel LW, Wolchok JD, Houghton AN, **Perales MA**, van den Brink M. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses following murine allogeneic bone marrow transplantation. *Blood* 2009; 113:1574-80.
 29. Goldberg JD, Kamboj M, Ford R, Kiehn TE, Gilhuley K, **Perales MA**. "Kennel Cough" in a patient following allogeneic hematopoietic stem cell transplant. *Bone Marrow Transplant* 2009; 44:381-2.

30. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, **Perales MA**, Altan-Bonnet G, Wolchok JD, Houghton AN. Self-antigen specific CD8+ T cell precursor frequency determines the quality of the anti-tumor immune response. *J Exp Medicine* 2009; 206:849-66.
31. Moskowitz AJ, **Perales MA**, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z, Vanak J, Zelenetz AD, Moskowitz CH. Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma. *Br. J. Hem* 2009; 146:158-163.
32. **Perales MA**, Jenq R, Goldberg JD, Wilton A, Lee SSE, Castro-Malaspina HR, Hsu K, Papadopoulos EB, van den Brink MRM, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O'Reilly RJ, Kewalramani T, Young JW, Jakubowski AA. Second-line age adjusted International Prognostic Index predicts overall survival in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic stem cell transplant. *Bone Marrow Transplant* 2010; 45:1408-1416.
33. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymerman D, Kim SC, Diab A, Rizzuto G, Duan F, **Perales MA**, Merghoub T, Houghton AN, Wolchok JD. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. *PLoS One* 2010; 5(5):e10436.
34. Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolanos-Meade J, Weisdorf D; Blood and Marrow Clinical Trials Network. Graft-versus-host disease treatment: predictors of survival. *Biol Blood Marrow Transplant*. 2010; 16:1693-1699. (co-author as participating investigator in BMT CTN study)
35. Barker JB, Doubrovina E, Sauter C, Jaroscak JJ, **Perales MA**, Doubrovin M, Prockop SE, Koehne G, O'Reilly RJ. Successful Treatment of Epstein-Barr Virus (EBV)-Associated Post-Transplant Lymphoma after Cord Blood Transplant using Third-Party EBV-Specific Cytotoxic T-Lymphocytes. *Blood* 2010; 116:5045-5049. PMID 2086724
36. Ponce DM, Zheng J, Gonzales A, Lubin M, Heller G, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq RR, Koehne G, Papadopoulos EB, **Perales MA**, van den Brink MR, Young JW, Boulad F, Kernan NA, Kobos R, Prockop S, Scaradavou A, Small T, O'Reilly RJ, Barker JN. Reduced Late Mortality Risk Contributes to Similar Survival after Double Unit Cord Blood Transplantation as Compared with Related and Unrelated Donor Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplan*. 2011; 17:1316-1326. PMID 21232625
37. Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G, Hsu KC, **Perales MA**, Papanicolaou G, van den Brink MR, O'Reilly RJ, Young JW, Papadopoulos EB. T-cell depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. *Biol Blood Marrow Transplan* 2011; 17:1335-1342. PMID 21232623
38. Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, Hawke R, **Perales MA**, van den Brink MR, Giralt S, Papanicolaou G, Scaradavou A, Small TN, Barker JN. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. *Biol Blood Marrow Transplant*. 2011; 17:1460-1371. PMID: 21310254
39. Goldberg JD, Chou JF, Horwitz S, Teruya-Feldstein J, Barker JN, Boulad F, Castro-Malaspina H, Giralt S, Jakubowski AA, Koehne G, van den Brink MRM, Young JW, Zhang Z, Papadopoulos EB, **Perales MA**. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplantation. *Leukemia and Lymphoma* 2012; 53:1124-1129. PMID: 22136377
40. Moskowitz CH, Matasar M, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, Horwitz S, Moskowitz AJ, Noy A, Palomba ML, **Perales MA**, Portlock C, Straus D, Maragulia J, Schoder H, Yahalom J. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross

- resistant, chemotherapy programs improves Event-Free Survival in patients with Hodgkin lymphoma. *Blood* 2012; 119:1665-70. PMID: 22184409
41. Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, **Perales MA**, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN. Outcome of Lower-Intensity Allogeneic Transplantation in non-Hodgkin Lymphoma After Autologous Transplant Failure. *Biol Blood Marrow Transplant.* 2012; 18:1255-64. PMID: 22198543
 42. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin KA, Socci ND, Viale A, **Perales MA**, Jenq RR, van den Brink M, Pamer EG. Intestinal Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. *Clin Infect Dis.* 2012; 55:905-14. PMID 22718773
 43. **Perales MA**, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB, Young JW, Jakubowski AA, Zaidi B, Gallardo H, Liu C, Rasalan T, Wolchok JD, Croughs T, Morre M, Devlin S, van den Brink MRM. Recombinant Human Interleukin-7 (CYT107) Promotes T Cell Recovery After Allogeneic Stem Cell Transplantation. *Blood* 2012; 120:4882-91. PMID 23012326
 44. Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MRM, **Perales MA**. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. *Bone Marrow Transplant,* 2013; 48:99-104
 45. Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MRM, Young JW, Boulad F, Kernan NA, O'Reilly RJ, Prockop SE, Yahalom J, Heller G, **Perales MA**. T-cell depleted stem-cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in 1st complete remission with a decreased risk of graft-versus-host disease. *Biol Blood Marrow Transplant.* 2013; 19:208-213 PMID: 22982534
 46. Moskowitz AJ, Hamlin PA Jr, **Perales MA**, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH. Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. *J Clin Oncol.* 2013; 31:456-460.
 47. Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, **Perales MA**, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? *Blood.* 2013; 121:2567-2573. PMC3612864
 48. van Heijst JWJ, Ceberio I, Lipuma LB, Samilo DW, Wasilewski GD, Gonzales AMR, Nieves JL, van den Brink MRM, **Perales MA**, Pamer EG. Quantitative assessment of human T-cell repertoire recovery after allogeneic hematopoietic stem cell transplantation. *Nature Medicine* 2013; 372-377. PMC3594333
 49. Ponce DM, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S, Goldberg JD, Hanash AM, Jakubowski A, Jenq R, Papadopoulos EB, **Perales MA**, van den Brink MR, Young JW, Boulad F, O'Reilly RJ, Prockop S, Small TN, Scaradavou A, Kernan NA, Stevens CE, Barker JN. Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match. *Biol Blood Marrow Transplant.* 2013; 19:904-911. PMC3673765
 50. Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA, Scaradavou A, Giralt S, Goldberg JD, Koehne G, **Perales MA**, Young JW, Castro-Malaspina H, Jakubowski A, Papadopoulos EB, Barker JN. A Novel Reduced-Intensity Conditioning Regimen Induces a High

- Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit Cord Blood Transplantation. *Biol Blood Marrow Transplant*. 2013; 19:799-803. PMC3673764
51. Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MRM, Houghton AN, **Perales MA**. Enhanced responses to tumor immunization following total body irradiation are time-dependent. *PLoS One* 2013; 8:e82496.
 52. Marks DI, Woo KA, Zhong X, Appelbaum FR, Bachanova V, Barker JN, Brunstein CG, Gibson J, Kebriaei P, Lazarus HM, Olsson R, **Perales MA**, Pidala J, Savani B, Rocha V, Eapen M. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. *Haematologica*. 2014; 99:322-328. PMC3912963
 53. Sauter CS, Barker JN, Lechner L, Zheng J, Devlin SM, Papadopoulos EB, **Perales MA**, Jakubowski AA, Goldberg JD, Koehne G, Ceberio I, Giralt S, Zelenetz AD, Moskowitz CH, Castro-Malaspina H. A Phase 2 Study of a Non-myeloablative Allogeneic Stem Cell Transplant with Peri-transplant Rituximab in Patients with B-cell Lymphoid Malignancies: Favorably Durable Event-free Survival in Chemosensitive Patients. *Biol Blood Marrow Transplant*. 2014; 20:354-360.
 54. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, **Perales MA**, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. *J Clin Oncol*. 2014 Feb 1;32(4):273-81. PMID: 24344210
 55. Sauter CS, Chou JF, Papadopoulos EB, **Perales MA**, Jakubowski AA, Young JW, Scordo M, Giralt S, Castro-Malaspina H. A Prospective Study of an Alectuzumab Containing Reduced-intensity Allogeneic Stem Cell Transplantation Program in Patients with Poor-Risk and Advanced Lymphoid Malignancies. *Leuk Lymphoma*. 2014; 55(12):2739-47 PMID: 24528216
 56. Olson AL, Dahi PB, Zheng J, Devlin SM, Lubin M, Gonzales AM, Giralt SA, **Perales MA**, Papadopoulos EB, Ponce D, Young JW, Kernan NA, Scaradavou A, O'Reilly RJ, Small TN, Papanicolaou G, Barker JN. Frequent Human Herpesvirus-6 Viremia but Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Anti-thymocyte Globulin. *Biol Blood Marrow Transplant*. 2014; 20:787-793. PMID: 24548875
 57. Taur Y, Jenq RR, **Perales MA**, Littmann ER, Morjaria S, Ling L, No D, Gobourne A, Viale A, Dahi PB, Ponce DM, Barker JN, Giralt S, van den Brink M, Pamer EG. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. *Blood*. 2014; 124:1174-1182. PMID 24939656
 58. Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S, Ponce DM, Lechner L, Maloy MA, Goldberg JD, **Perales MA**. Sirolimus, tacrolimus and low-dose methotrexate based GVHD prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allo-HCT. *Leuk Lymphoma*. 2015; 56(3):663-70.
 59. Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, Lazarus HM, Laughlin MJ, Lill M, O'Brien T, **Perales MA**, Rocha V, Savani BN, Szwajcer D, Valcarcel D, Eapen M. Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Biol Blood Marrow Transplant*. 2014; 20:1418-1425. PMID 24892261
 60. Ustun C, Reiter A, Scott B, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan W, **Perales MA**, Shore T, Baurman H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhauser M, Papadopoulos EB, Böhm A,

- Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P. Hematopoietic Stem Cell Transplantation For Advanced Systemic Mastocytosis. *J Clin Onc* 2014; 32:3264-3274.
61. Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S, Goldberg JD, Hanash A, Hsu K, Jenq R, **Perales MA**, Sauter C, van den Brink MR, Young JW, Brentjens R, Kernan NA, Prockop SE, O'Reilly RJ, Scaradavou A, Paczesny S, Barker JN. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. *Blood*. 2015 125:199-205.
 62. Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, Matasar MJ, Maragulia J, Giralt SA, **Perales MA**, Moskowitz CH, Sauter CS. Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2014; 20:2004-2009.
 63. Dahi PB, **Perales MA**, Devlin SM, Olson A, Lubin M, Gonzales AM, Scaradavou A, Kernan NA, O'Reilly RJ, Giralt S, Jakubowski A, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Papanicolaou G, Barker JN. Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. *Leuk Lymphoma*. 2015; 56(6):1799-805.
 64. Eapen M, Logan B, Horowitz MM, Zhong X, **Perales MA**, Lee S, Rocha V, Soiffer R, Champlin RE. Bone Marrow or Peripheral Blood for Reduced Intensity Conditioning Unrelated Donor Transplantation. *J Clin Onc* 2015; 33:364-369.
 65. Ceberio I, Dai K, Devlin SM, Barker JN, Castro-Malaspina H, Goldberg JD, Giralt S, Adel NG, **Perales MA**. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. *Bone Marrow Transplant* 2015; 50:438-443.
 66. Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, **Perales MA***, Kebriaei P*. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. *Bone Marrow Transplant* 2015; 50:493-498. *shared senior authorship.
 67. Harnicar S, Ponce DM, Hilden P, Zheng J, Devlin SM, Lubin M, Pozotrigio N, Mathew S, Adel N, Kernan NA, O'Reilly R, Prockop S, Scaradavou A, Hanash A, Jenq R, van den Brink M, Giralt S, **Perales MA**, Young JW, Barker JN. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease After Double-Unit Cord Blood Transplantation. *Biol Blood Marrow Transplant*. 2015; 21:920-925.
 68. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, **Perales MA**, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. *Lancet Oncology*. 2015; 16:284-292.
 69. Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L, Gobourne AC, Miller LC, Docampo MD, Peled JU, Arpaia N, Cross JR, Peets TK, Lumish MA, Shono Y, Dudakov JA, Poeck H, Hanash AM, Barker JN, **Perales MA**, Giralt SA, Pamer EG, van den Brink MR. Intestinal *Blautia* is associated with reduced death from graft-versus-host disease. *Biol Blood Marrow Transplant*. 2015; 21(8):1373-83
 70. Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, **Perales MA**, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino

- R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W. The Impact of Graft Versus Host Disease on Relapse Rate in Patients with Lymphoma Depends on the Histological Sub-Type and the Intensity of the Conditioning Regimen. *Biol Blood Marrow Transplant*. 2015; 21(10):1746-53.
71. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljritawi OS, Armand P, Antin JA, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, **Perales MA**, Pingali SR, Porter DL, Riches MR, Ringdén OTH, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. *Blood* 2015; 126(8):1033-40.
 72. Mussetti A, Devlin SM, Castro-Malaspina HR, Barker JN, Giralt SA, Zelenetz AD, Sauter CS, **Perales MA**. Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era. *Bone Marrow Transplantation* 2015; 50(10):1293-8.
 73. Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, Dahi P, Hsu K, Jakubowski AA, Kernan NA, Koehne G, O'Reilly RJ, Papadopoulos EB, **Perales MA**, Sauter C, Scaradavou A, Tamari R, van den Brink MR, Young JW, Giralt S, Barker JN. High Disease-Free Survival with Enhanced Protection Against Relapse After Double-Unit Cord Blood Transplantation when Compared to T-cell Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. *Biol Blood Marrow Transplant*. 2015; 21(11):1985-93.
 74. Tamari R, Chung S, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, **Perales MA**, Ponce DM, Sauter CS, Maloy MA, Herman DY, Klimek V, Young JW, O'Reilly RJ, Giralt SA, Castro-Malaspina H. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. *Biol Blood Marrow Transplant*. 2015; 21(12):2106-14.
 75. Shah GL, Shune L, Purtill D, Devlin S, Lauer E, Lubin M, Bhatt V, McElrath C, Kernan NA, Scaradavou A, Giralt S, **Perales MA**, Ponce DM, Young JW, Shah M, Papanicolaou G, Barker JN. Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. *Biol Blood Marrow Transplant*. 2015; 21(12):2160-6.
 76. Ponce DM, Eapen M, Sparapani R, O'Brien TA, Chan KW, Chen J, Craddock J, Schultz KR, Wagner JE, **Perales MA***, Barker JN*. In vivo T-cell depletion with myeloablative regimens on outcomes after cord blood transplantation for acute lymphoblastic leukemia in children. *Biol Blood Marrow Transplant*. 2015; 21(12):2173-9. *shared senior authorship.
 77. Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, DiPersio JF, Fernandez-Viña M, Hartzman RJ, Horowitz MM, Hurley CK, Karanes C, Maiers M, Mueller CR, **Perales MA**, Setterholm M, Woolfrey AE, Yu N, Eapen M. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. *Blood*. 2016; 127(2):260-7.
 78. Neofytos D, Huang YT, Cheng K, Cohen N, **Perales MA**, Barker J, Giralt S, Jakubowski A, Papanicolaou G. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. *Clin Infect Dis*. 2015 Dec 1;61 Suppl 6:S652-61
 79. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, **Perales MA**, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. *Blood*. 2015 Dec 15. [Epub ahead of print]

80. Barba P, Burns LJ, Litzow MR, Juckett MB, Komanduri KV, Lee SJ, Devlin SM, Costa LJ, Khan S, King A, Klein A, Krishnan A, Malone A, Mir M, Moravec C, Selby G, Roy V, Cochran M, Stricherz MK, Westmoreland MD, **Perales MA***, Wood WA*. Success of an International Learning Healthcare System in Hematopoietic Cell Transplantation: the American Society of Blood and Marrow Transplantation Clinical Case Forum. *Biol Blood Marrow Transplant*. 2015 [Epub ahead of print] *shared senior authorship.
81. Shaffer BC, Le Ludec JB, Forlenza C, Jakubowski AA, **Perales MA**, Young JW, Hsu KC. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2016 Jan 6. [Epub ahead of print]
82. Lunning MA, Migliacci JC, Hilden P, Devlin SM, Castro-Malaspina H, Giralt S, **Perales MA**, Zelenetz AD, Moskowicz CH, Sauter CS. The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤ 12 months. *Br J Haematol*. 2016 Apr;173(2):260-4.
83. Dahi PB, Morawa E, **Perales MA**, Zabor EC, Devlin S, Maloy M, Castro-Malaspina H, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Giralt SA. Low Incidence of GVHD with T-Cell Depleted Allografts Facilitate Further Treatments for Post-Transplantation Relapse in AML and MDS. *Bone Marrow Transplantation* 2016 (Accepted)
84. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, **Perales MA**, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M. Allogeneic Transplantation Provides Durable Remission in a Subset of DLBCL Patients Relapsing after Autologous Transplantation. *Br. J. Hem* 2016 (accepted)
85. Hobbs GS, Kaur N, Hilden P, Ponce D, Cho C, Castro-Malaspina HR, Giralt S, Goldberg JD, Jakubowski AA, Papadopoulos EB, Sauter C, Koehne G, Yahalom J, Delvin S, Barker JN, **Perales MA**. A Novel Reduced Intensity Conditioning Regimen for Patients with High Risk Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation. *Bone Marrow Transplantation* 2016 (Accepted)
86. Morjaria S, Epstein DJ, Romero FA, Taur Y, Seo SK, Papanicolaou GA, Hatzoglou V, Rosenblum M, **Perales MA**, Scordo M, Kaltsas A. Toxoplasma Encephalitis in Atypical Hosts at an Academic Cancer Center. *Open Forum Infect Dis*. 2016 Mar 30;3(2):ofw070
87. Huang YT, Neofytos D, Foldi J, Kim SJ, Maloy M, Chung D, Castro-Malaspina H, Giralt SA, Papadopoulos E, **Perales MA**, Jakubowski AA, Papanicolaou GA. Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1480-6.
88. Spitzer B, **Perales MA**, Kernan NA, Prockop SE, Zabor EC, Webb N, Castro-Malaspina H, Papadopoulos EB, Young JW, Scaradavou A, Kobos R, Giralt SA, O'Reilly RJ, Boulad F. Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1449-54.
89. Isa F, Saito K, Huang YT, Schuetz A, Babady NE, Salvatore S, Pessin M, van Besien K, **Perales MA**, Giralt S, Sepkowitz K, Papanicolaou GA, Soave R, Kamboj M. Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. *Clin Infect Dis*. 2016 Aug 15;63(4):565-8.
90. Kim HT, Zhang MJ, Woolfrey AE, St Martin A, Chen J, Saber W, **Perales MA**, Armand P, Eapen M. Donor and recipient sex in allogeneic stem cell transplantation: what really matters. *Haematologica*. 2016 Jun 27. [Epub ahead of print]

91. Karandikar UC, Crawford SE, Ajami NJ, Murakami K, Kou B, Ettayebi K, Papanicolaou GA, Jongwutiwes U, **Perales MA**, Shia J, Mercer D, Finegold MJ, Vinjé J, Atmar RL, Estes MK. Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients. *J Gen Virol*. 2016 Jul 12. doi: 10.1099/jgv.0.000545. [Epub ahead of print]
92. Bhatt V, Shune L, Lauer E, Lubin M, Devlin SM, Scaradavou A, Parameswaran R, **Perales MA**, Ponce DM, Mantha S, Kernan NA, Barker JN. Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab. *Bone Marrow Transplant*. 2016 Dec;51(12):1579-1583.
93. Cho C, **Perales MA**. Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab. *Bone Marrow Transplant*. 2016 Dec;51(12):1620-1621.
94. Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MR, Young JW, O'Reilly RJ, Giralt SA, **Perales MA**. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2017 Jan;23(1):67-74.
95. Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MR, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, **Perales MA**, Ponce DM. Ex Vivo CD34+ Selected T-Cell Depleted (TCD) Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome is Associated with Low Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD) and High Treatment Response. *Biol Blood Marrow Transplant*. 2016 [Epub ahead of print]
96. Goldberg JD, Zheng J, Ratan R, Small TN, Lai KC, Boulad F, Castro-Malaspina H, Giralt SA, Jakubowski AA, Kernan NA, O'Reilly RJ, Papadopoulos EB, Young JW, van den Brink MR, Heller G, **Perales MA**. Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. *Leuk Lymphoma*. 2017 [Epub ahead of print]
97. Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, **Perales MA**, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescout W, Thiebaut-Bertrand A, François S, Stamatoullas-Bastard A, Rohrlich PS, Labussière Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P. Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant After PD-1 Blockade in Relapsed/Refractory Lymphoma. *Blood*. 2017 Epub ahead of print]

Guidelines, position papers

1. Burns LJ, Gajewski JL, Majhail NS, Navarro W, **Perales MA**, Shereck E, Selby GB, Snyder EL, Woolfrey AE, Litzow MR. Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program's System Capacity Initiative Physician Workforce Group Report. *Biol Blood Marrow Transplant*. 2014; 20:617-621. PMID: 24508838
2. Bubalo J, Carpenter PA, Majhail N, **Perales MA**, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN. Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee. *Biol Blood Marrow Transplant*. 2014; 20:600-616.
3. Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, **Perales MA**, Cutler CS, Bensinger W, Litzow MR, Mohty M, Champlin RE, Giralt S, Carpenter

- PA. Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2014; 20:1262-1273. PMID: 24816581
4. **Perales MA**, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat U, Reddy NM, Shea TC, Vose JM, Schriber J, Savani BN, Carpenter PA. Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015; 21(6):971-83.
 5. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, **Perales MA**, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giral S, Savani BN. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015; 21(7):1155-66.
 6. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, **Perales MA**, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1348-56.
 7. Palmer J, McCune JS, **Perales MA**, Marks D, Bubalo J, Mohty M, Wingard J, Paci A, Hassan M, Bredeson C, Pidades J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA. Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. *Biol Blood Marrow Transplant*. 2016 Jul 29. [Epub ahead of print].
 8. Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, **Perales MA**, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorrow M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2016 Dec;22(12):2117-2125.

Invited Editorials

1. **Perales MA**, Wolchok JD. CD4 Help and Tumor Immunity: Beyond the Activation of Cytotoxic T Lymphocytes (editorial). *Annals of Surgical Oncology*, 2004; 11:881-882.
2. **Perales MA**. Adoptive therapy of CMV-specific T lymphocytes: Is less more? (editorial) *Clinical Infectious Diseases*, 2011; 52:58-60.
3. Soriano G, **Perales MA**. Adenovirus viremia and infection after reduced intensity allogeneic hematopoietic stem cell transplant: Should we institute a routine screening program? (editorial) *Clinical Infectious Diseases*. 2012; 55:1371-2.
4. **Perales MA**, van den Brink, MRM. Immune recovery after allogeneic hematopoietic stem cell transplant: Is it time to revisit how patients are monitored? (Commentary) *Biol Blood Marrow Transplant*. 2012; 18:1617-9.
5. **Perales MA**. Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines. *Biol Blood Marrow Transplant*. 2016 Dec;22(12):2113-2114.

Invited Reviews

1. **Perales MA**, Blachere NE, Engelhorn ME, Ferrone CR, Gold JS, Gregor PD, Noffz G, Wolchok JD, Houghton AN. Strategies to overcome immune ignorance and tolerance. *Seminars in Cancer Biology*, 2002; 12:63-71.
2. **Perales MA**, Wolchok JD. Melanoma vaccines. *Cancer Investigation*, 2002; 20:1012-1026.
3. Chang DZ, Lomazow W, Somberg CJ, Stan R, **Perales MA**. Granulocyte-Macrophage Colony Stimulating Factor: an adjuvant for cancer vaccines. *Hematology*, 2004; 9:207-215.
4. Diab A, Cohen AD, Alpdogan O, **Perales MA**. Interleukin-15: Targeting CD8⁺ T cells for immunotherapy. *Cytotherapy*, 2005; 7:23-35.
5. Goldberg GL, Zakrzewski JL, **Perales MA**, van den Brink MR. Clinical strategies to enhance T cell reconstitution. *Semin Immunol*, 2007; 19:289-296.
6. Hirschhorn-Cymerman D, **Perales MA**. Cytokine-FC fusion genes as molecular adjuvants for DNA vaccines. *Methods Mol Biol*. 2010; 651:131-55.
7. Vadhan-Raj S, Goldberg JD, **Perales MA**, Berger DP, van den Brink MR. Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. *J Cell Mol Med*. 2013; 17(11):1371-84.
8. Reddy NM, **Perales MA**. Stem cell transplantation in Hodgkin Lymphoma. *Hematology/Oncology Clinics of North America* 2014; 28(6):1097-112.
9. Mussetti A, Kumar A, Dahi PB, **Perales MA**, Sauter CS. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. *Blood Rev* 2015; 29(3):143-52.
10. Hobbs G, **Perales MA**. Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. *Journal of Clinical Medicine* 2015, 4(3):488-503.
11. Lucchini G, **Perales MA**, Veys P. Immune reconstitution after cord blood transplantation: peculiarities, clinical implications and management strategies. *Cytotherapy*. 2015 Jun;17(6):711-22.
12. Thompson MA, Majhail NS, Wood WA, **Perales MA**, Chaboissier M. Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. *Curr Hematol Malig Rep*. 2015 Oct 9. [Epub ahead of print]
13. **Perales MA**, Sauter C, Armand P. Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. *Biol Blood Marrow Transplant*. 2015 [Epub ahead of print]
14. van den Brink MR, Velardi E, **Perales MA**. Immune reconstitution following stem cell transplantation. *Hematology Am Soc Hematol Educ Program*. 2015 Dec 5;2015(1):215-9.
15. **Perales MA**, Drake EK, Pemmaraju N, Wood WA. Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer. *Curr Hematol Malig Rep*. 2016 Feb 18. [Epub ahead of print]

Books, book chapters

1. **Perales MA**, Chapman PB. Immunizing against partially-defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses. In: Giaccone G, Schilsky R, Sondel P, eds. *Cancer Chemotherapy & Biological Response Modifiers*, 2005; 22:749-60.
2. Saenger YM, Jenq R, **Perales MA**. Immunomodulatory molecules of the immune system. In: Kaufman HL, Wolchok JD, eds. *General Principles of Tumor Immunology*. Springer, 2007; 67-121.
3. **Perales MA**, Wolchok JD, Kaufman HL. Vaccines as targeted cancer therapy. In: Kaufman HL, Wadler SC, Antman KA, eds. *Molecular Targeting in Oncology*. The Humana Press, Inc., 2008:447-469.

4. **Perales MA**, Dudakov JA, Hanash AM, van den Brink MRM. Strategies to improve post-transplant immunity. In Socie G, Blazar B, eds. *Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation*. Elsevier, 2013:123-142.
5. Kumar A, **Perales MA**. Allogeneic Transplantation. In Drillon AE, Postow MA, eds. *Pocket Oncology*. Wolters Kluwer, 2014: 268-269.
6. Goldberg JD, **Perales MA**. T cell depletion and hematopoietic stem cell transplantation. In Abutalib S, Markam M, eds. *Cancer Consult, Expertise for Clinical Practice*. Wiley, 2014: 421-425.
7. Bahrami Dahi P, Hobbs G, **Perales MA**. Use of transplantation in lymphoma. In Savani BN, Mohty M, Eds. *Clinical Guide to Transplantation in Lymphoma*. Wiley (2015): 23-29.
8. Dudakov JA, **Perales MA**, van den Brink MRM. Immune reconstitution following hematopoietic cell transplantation. In: *Thomas' Hematopoietic Cell Transplantation, 5th Edition*. In press.

Other

1. ASBMT Education Committee, ABIM Practice Improvement Module – Chronic Graft versus Host Disease, 2012. (Member of the PIM Development Committee)
2. ASBMT Education Committee, ABIM Practice Improvement Module – Infection Control, 2012. (Member of the PIM Development Committee)
3. Early complications of BMT (Webinar). NMDP, System Capacity Initiative. (on-line posting in 2013)
http://bethematch.org/Apps/SCI-Presentations/EarlyComplicationsBMT/Early_Complications_of_BMT.html

Invited Seminars

- | | |
|------------|---|
| 07/27/2001 | Molecular adjuvants for DNA vaccines. Earle A. Chiles Research Institute, Providence Portland Medical Center, Providence, OR. |
| 04/25/2002 | DNA vaccines for Cancer. Hôpital Henri Mondor, Paris, France. |
| 07/16/2003 | DNA vaccines for cancer: From bench to bedside. Tufts – New England Medical Center, Boston, MA. |
| 07/24/2003 | DNA vaccines for cancer. Workshop speaker. Commercializing Therapeutic Cancer Vaccines, Washington, DC. |
| 11/22/2004 | T-cell depleted allogeneic bone marrow transplantation, a platform for immunotherapy. Hematology-Oncology Grand Rounds, University of Maryland Greenebaum Cancer Center, Baltimore, MD. |
| 11/30/2004 | Bench Meets Business - Focus: Cancer Immunotherapy. New York, NY |
| 08/17/2005 | Invasive fungal infections in patients undergoing allogeneic bone marrow transplantation. Fox Chase – Temple University, Philadelphia, PA. |
| 10/25/2005 | Mouse models for DNA tumor immunization after allogeneic transplantation. Translational Research Seminar Series, Memorial Sloan-Kettering Cancer Center, New York, NY. |
| 03/30/2006 | Management of invasive fungal infections in allogeneic bone marrow transplantation. Hematology-Oncology Grand Rounds, SUNY Upstate Medical University, Syracuse, NY |
| 06/23/2006 | Management of invasive fungal infections in allogeneic bone marrow transplantation. Blood and Marrow City Wide Conference, Strong Memorial Hospital, Rochester, NY |
| 09/05/2007 | Anti-Tumor Vaccination in the setting of Lymphodepletion and Adoptive Cell Transfer. Hematology/Oncology Grand Rounds, New York Hospital, New York, NY. |

- 10/11/2007 Anti-tumor vaccination in the setting of lymphodepletion and adoptive cell transfer. Cancer Vaccines/ Adjuvants/ Delivery for the next Decade 2007, Heidelberg, Germany.
- 08/18/2008 Management of invasive fungal infections in allogeneic bone marrow transplantation. Stem Cell Conference, St. Louis University, St Louis, MI.
- 10/29/2008 Management of invasive fungal infections in allogeneic bone marrow transplantation. Hematology/Oncology Grand Rounds, Hahnemann University Hospital, Philadelphia, PA.
- 11/13/2008 Anti-Tumor Vaccination in the setting of Lymphodepletion and Adoptive Cell Transfer. Hematology/Oncology Seminar. University of Texas Southwestern Medical Center, Dallas, TX.
- 09/25/2009 Transplant Strategies in Refractory Leukemia. Princess Margaret Hospital Transplant 2009, Toronto, Canada.
- 10/15/2009 Management of invasive fungal infections in allogeneic bone marrow transplantation. Bone Marrow Transplant Supportive Care Rounds. Northside Hospital, Atlanta, GA.
- 11/11/2009 Cancer Vaccines and Adoptive Cellular Therapy: Insights from pre-clinical models. Cancer Vaccines/ Adjuvants/ Delivery for the next Decade 2009, Dublin, Ireland.
- 01/13/2011 Targeting acute lymphoblastic leukemia with T-cell precursors in allogeneic hematopoietic stem cell transplant. Center for Cell Engineering Annual Retreat Roundtable, Memorial Sloan-Kettering Cancer Center, New York, NY.
- 03/24/2011 Cancer Vaccines and Cellular Therapy: From bench to bedside. Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- 04/01/2011 Recombinant human interleukin-7 (CYT107) enhances T-cell recovery without causing graft-versus-host disease following T-cell depleted allogeneic hematopoietic stem cell transplantation. Cytheris, Issy-Les-Moulineaux, France.
- 04/12/2011 No longer waiting for Godot: Strategies to enhance immune recovery following T-cell depleted allogeneic hematopoietic stem cell transplantation. Hematology-Oncology Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY.
- 07/22/2011 Strategies to enhance immune recovery following T-cell depleted allogeneic stem cell transplantation. Hematology-Oncology Grand Rounds, SUNY Downstate Medical Center, Brooklyn, NY.
- 01/12/2012 Gene-modified T-cell precursors in patients undergoing allogeneic stem cell transplant: a novel platform for tumor-specific therapy. Center for Cell Engineering Annual Retreat Roundtable, Memorial Sloan-Kettering Cancer Center, New York, NY.
- 02/23/2012 Strategies to enhance immune recovery following allogeneic stem cell transplantation. University of Arkansas Medical Sciences Winthrop P. Rockefeller Cancer Institute, Little Rock, AR.
- 04/20/2012 Novel approaches to enhance immune recovery after allogeneic stem cell transplantation. Baptist Memorial Hospital, Memphis, TN.
- 06/01/2012 The role of stem cell transplant in multiple myeloma. ASCO Clinical Care in Oncology for the Advanced Practice Provider Seminar, Chicago, IL.
- 06/08/2012 Generation of T cell precursors from human cord blood CD34+ stem cells: applications for immune recovery and tumor targeting. International Cord Blood Symposium, San Francisco, CA.
- 08/23/2012 Enhancing Immune Recovery Post BMT: Pre-Clinical and Clinical Experience with IL-7. Washington University School of Medicine, St. Louis, MI.
- 01/31/2013 Towards lymphoid progenitor cell therapy. Center for Cell Engineering Annual Retreat Roundtable, Memorial Sloan-Kettering Cancer Center, New York, NY.
- 02/16/2013 Early complications post BMT. BMT Clinical Education Conference. BMT Tandem Meetings, Salt Lake City, UT.

- 03/04/2013 Complications of stem cell transplantation. Hematology and Medical Oncology Board Review – MSKCC, New York, NY.
- 04/16/2013 Early complications post BMT. Faculty of Medicine, University of Barcelona, Barcelona, Spain
- 04/16/2013 Practicing Medicine in the USA after training in Europe: a how-to-guide. Faculty of Medicine, University of Barcelona, Barcelona, Spain
- 04/17/2013 Immune reconstitution after allogeneic HSCT. Division of Hematology-Oncology Special Seminar. University Hospital Clinic de Barcelona, Barcelona, Spain
- 06/17/2013 Immune Reconstitution after Allogeneic Stem Cell Transplant: From Bench to Bedside. Istituto Nazionale dei Tumori di Milano, Milan, Italy.
- 07/03/2013 Immune Reconstitution after Allogeneic Stem Cell Transplant, Ospedale Santa Maria della Misericordia, Perugia, Italy.
- 11/12/2013 Unmet Medical Needs in AML and ALL: Strategies to Improve Transplant Outcomes, Seattle Genetics, Bothell, WA
- 02/10/2014 Immune Reconstitution after Allogeneic Stem Cell Transplant, University of Nebraska Medical Center, Omaha, NE.
- 02/26/2014 BMT CTN 1301 PROGRESS II (CNI-Free GVHD Prophylaxis), Blood and Marrow Transplantation Clinical Trials Network Investigators Meeting, BMT Tandem Meetings, Dallas, Tx.
- 03/01/2014 Immune Reconstitution after Stem Cell Transplantation, BMT Clinical Education Conference. BMT Tandem Meetings, Dallas, Tx.
- 03/02/2014 Next Generation Sequencing to Characterize Post-Transplant T cell Recovery, BMT Tandem Meetings, Dallas, Tx.
- 03/09/2014 Complications of hematopoietic stem cell transplantation. Hematology and Medical Oncology Board Review – MSKCC, New York, NY.
- 04/25/2014 What is the optimal therapy for CLL patients failing to achieve PR with chemoimmunotherapy? Stem Cell Transplant. Great Debates & Updates in Hematologic Malignancies 2014, New York, NY.
- 09/11/2014 Novel insights into immune reconstitution after stem cell transplantation, Yale Cancer Center, New haven, CT.
- 02/13/2015 BMT CTN1301 – Progress II Trial – A three arm randomized phase III trial to determine the best method for GVHD prevention following allogeneic transplant in acute leukemia and MDS. BMT Tandem Meetings, San Diego, CA
- 03/08/2015 Complications of hematopoietic stem cell transplantation. Hematology and Medical Oncology Board Review – MSKCC, New York, NY.
- 08/10/2015 Immune reconstitution after stem cell transplantation. Cedars-Sinai Medical Center, Los Angeles, CA.
- 08/21/2015 Trasplante Haploidéntico: ¿Está listo para ser el protagonista? – *Haploidentical transplant: ready for prime time?* Second Annual Meeting of Research in Hematology and Oncology, Colombian Society of Hematology and Oncology, Santa Marta, Colombia.
- 10/13/2015 Clinical Trials of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed or Refractory B-ALL and B-NHL. CIBMTR Cellular Therapy Registry Forum, Milwaukee, WI.
- 10/19/2015 Viral-Specific T-Cells for Treatment of Rituximab Refractory EBV+ B-Cell Lymphoma and Refractory CMV. Hospital La Fe, Valencia, Spain.
- 10/22/2015 La depleción de células T en el trasplante alogénico de progenitores hematopoyéticos de donante no emparentado - *Role of T-cell Depletion in Allogeneic Stem Cell Transplant*

- from Unrelated Donors*. LVII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia, Valencia, Spain.
- 11/07/2015 Post-Transplant Infectious Complications and the Role of Cellular Therapy (Joint session with John R. Wingard), National Marrow Donor Program Council Meeting, Minneapolis, MN
- 12/11/2015 Reconstitution Immunitaire après Greffes de Cellules Souches Allogéniques. *Immune reconstitution after allogeneic stem cell transplantation*. Hopital Maisonneuve-Rosemont, Montreal, Canada.
- 01/21/2015 Immune Reconstitution after Hematopoietic Stem Cell Transplantation. University of Michigan, Ann Arbor, MI.
- 02/19/2016 Time to hit the Accelerator: Adoptive cell therapy and checkpoint inhibitors in multiple myeloma. BMT Tandem Meetings, Honolulu, HI.
- 03/06/2016 Complications of hematopoietic stem cell transplantation. Hematology and Medical Oncology Board Review – MSKCC, New York, NY.
- 03/22/2016 Live from New York: Update on CART and CTL studies at MSKCC. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- 04/01/2016 Live from New York: Update on CART and CTL studies at MSKCC. Hospital Universitari Vall d'Hebron, Barcelona, Spain
- 04/05/2016 Ex vivo T-cell Depletion: Benefits of CD34+ selection in patients with leukemia and MDS. European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Valencia, Spain.
- 04/09/2016 Microbioma y Trasplante De Células Progenitoras Hematopoyéticas. *Microbiome Studies in recipients of hematopoietic stem cell transplants*. Simposio Internacional De Terapias Biológicas En Hematología, Querétaro, México.
- 04/09/2016 Trasplante Autólogo Como Plataforma Para Nuevas Inmunoterapias En Linfoma Y Mieloma. *Autologous stem cell transplant as a platform for novel immunotherapies in lymphoma and myeloma*. Simposio Internacional De Terapias Biológicas En Hematología, Querétaro, México.
- 05/20/2016 Live from New York: Update on CART and CTL studies at MSKCC, Grand Rounds, University of Indiana, IN.
- 09/11/2016 Checkpoint Inhibitors and HSCT, European Society for Blood and Marrow Transplantation (EBMT) International Transplant Course, Barcelona, Spain.

Updated 1/9/17